JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB259113

Human SIK1 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

SIK1 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.
1 Images
Sanger Sequencing - Human SIK1 knockout HeLa cell lysate (AB259113)
  • Sanger seq

Unknown

Sanger Sequencing - Human SIK1 knockout HeLa cell lysate (AB259113)

Homozygous : 1 bp insertion in exon2

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.

Disease

Adenocarcinoma

style
left-column

Complementary Products

Proteins & Peptides

AB268969

Recombinant human SIK1 protein (Active)

Functional Studies - Recombinant human SIK1 protein (Active) (AB268969)

  • 0
  • 0
Cell Lines & Lysates

AB265681

Human SIK1 knockout HeLa cell line

Sanger Sequencing - Human SIK1 knockout HeLa cell line (AB265681)

  • 0
  • 0
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab259113-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human SIK1 knockout HeLa cell lysate", "number":"AB259113-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB259113-CMP02", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
SIK1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SIK1 also known as salt-inducible kinase 1 functions as a serine/threonine-protein kinase. This protein has a mass of approximately 85 kDa. SIK1 expression occurs in multiple tissues with high levels found in the brain and cardiac muscle. Mechanically SIK1 phosphorylates a variety of substrates which modifies their activity or stability. By adding phosphate groups to specific sequences it alters protein functions and cellular pathways impacting cellular processes like metabolism and transcription.
Biological function summary

Salt-inducible kinase 1 plays an important role in regulating cellular responses to metabolic stress and hormonal signaling. It forms part of a kinase complex where it operates alongside other kinases and regulatory proteins to modulate gene expression and metabolic pathways. SIK1 influences gluconeogenesis and lipogenesis processes essential for maintaining energy homeostasis. The regulation by SIK1 of these processes is essential to adapt to changes in cellular environment and energy requirements.

Pathways

Salt-inducible kinase 1 is an important regulator within the cAMP signaling pathway and the AMPK signaling pathway. In the cAMP pathway SIK1 interacts with protein kinase A (PKA) contributing to the modulation of the transcription factor CREB. In the AMPK pathway SIK1 indirectly affects energy balance by influencing downstream genes involved in glucose production and fatty acid metabolism. These interactions highlight SIK1's place in controlling energy and metabolic homeostasis in response to external stimuli.

Salt-inducible kinase 1 has been linked to conditions such as cardiac hypertrophy and type 2 diabetes. In cardiac hypertrophy SIK1 affects the remodeling of cardiac tissue potentially interacting with the protein HDAC which is important in regulating cardiac muscle gene expression. In type 2 diabetes the altered activity or expression of SIK1 could disrupt normal glucose metabolism while pathways involving proteins like AMPK may contribute to insulin resistance. Understanding these relationships can aid in developing therapeutic strategies targeting SIK1-related pathways.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com